Direxion Daily S&P Biotech Bull 3X Shares (LABU)
| Assets | $1.20B |
| Expense Ratio | 1.01% |
| PE Ratio | n/a |
| Shares Out | 177.31M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +16.55% |
| Volume | 20,557,351 |
| Open | 6.62 |
| Previous Close | 6.72 |
| Day's Range | 6.57 - 6.89 |
| 52-Week Low | 4.06 |
| 52-Week High | 13.19 |
| Beta | 3.00 |
| Holdings | 157 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.
Top 10 Holdings
247.18% of assets| Name | Symbol | Weight |
|---|---|---|
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 44.47% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 36.36% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 33.82% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 28.95% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 28.76% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 25.61% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 25.58% |
| DREYFUS GOVT CASH MAN INS | n/a | 14.79% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 7.05% |
| ImmunoGen, Inc. | IMGN | 1.79% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2019 | $0.00531 | Dec 31, 2019 |
| Sep 24, 2019 | $0.01084 | Oct 1, 2019 |
| Jun 25, 2019 | $0.03745 | Jul 2, 2019 |
| Mar 19, 2019 | $0.10973 | Mar 26, 2019 |
| Dec 27, 2018 | $0.09621 | Jan 4, 2019 |
| Sep 25, 2018 | $0.0954 | Oct 2, 2018 |
News
Top Performing Leveraged/Inverse ETFs: 05/07/2023
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the one-d...
Top Performing Leveraged/Inverse ETFs: 09/11/2022
Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Biotech Bounces in August as M&A Activity Increases
The biotech sector deflated, as most sectors did, in the first half of 2022. However, the sector is in the midst of a comeback as mergers and acquisitions rise, signaling increased activity.
Biotech Sector Is Garnering Interest From Investors Again
The biotech sector has been rallying as of late, evidenced by the S&P 500 Biotechnology Index up close to 9% within the past month. Of course, as we've seen so far in 2022, rallies are difficult to su...
Taking On Volatility With Geared ETFs
Direxion's Dave Mazza is seeing many traders using inverse and leveraged ETFs in the recent market movement.
Biotech Belonged to the Bears in Second Half of 2021
A bearish sentiment in biotechnology took over in the second half of 2021, providing gains for the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climbed almost 21% in the second half of 2021,...
Omicron Variant Is Boosting This Leveraged Biotech ETF
The Omicron variant re-asserted the strength of biotech equities, making the Direxion Daily S&P Biotech Bull 3x Shares (LABU) an option for traders. As investors turned up the risk dial, COVID-19 case...
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.
These 3 Popular ETFs Are Geared Toward Tactical Plays
Direxion's weekly ETF fund flows could shed light on what traders are thinking. The top three point to interest in long-term bond prices, biotech strength, and semiconductor weakness.
Biden's Infrastructure Can Put These 2 Leveraged Funds in Play
U.S. president Joe Biden's infrastructure plan is opening up ETF trading possibilities from multiple angles. One way is playing its healthcare component via funds like the Direxion Daily Healthcare Bu...
Up Over 100% in 2020 and 15% in 2021, ‘LABU' Isn't Holding Back
The biotechnology industry isn't backing down, with ETFs like the Direxion Daily S&P Biotech Bull 3x Shares (LABU) gaining over 15% to start the new year. More strength could be ahead as the global ec...
3 Direxion ETFs Top List of Best Leveraged Performers
Traders understand that when you add leverage to the mix, the results can be explosive gains, but on the flip side, it could be losses and a blown trading account. Yahoo Finance focused on top leverag...
Short Sellers Back Off From Biotech ETFs
The Covid-19 brought certain sectors serendipitous gains like technology, but even that space is now seeing sell-offs amid a September sell-off. As such, short sellers are coming in to reap the reward...
Biotech Has Been in a Steady Uptrend Even Through Covid-19
It’s been a memorable, if not unusual, summer of 2020, but it’s not stopping biotech bulls from charging forward. The sector has been on a steady uptrend despite the economic effects of Covid-19.
COVID Trade: The Race for an Ounce of Prevention
LABU: Which Biotechs Have Led the Covid Trade? Summertime is typically regarded as a notoriously choppy month for markets as volume tends to dissipate.
Heating Up: Three Leveraged ETFs For Summer Earnings
As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also mode...
With Biotech Scorching, Traders Show LABU Love
The coronavirus pandemic is fueling gains for biotechnology exchange traded funds this year and the leverage members of this group are participating in the fun.
3 Leveraged Healthcare ETFs Soaring This Month
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidem...